fda category 2 bulk drug substances bpc 157 compounding list has removed certain that were placed on the two and has announced it will consult the Pharmacy Advisory Committee (PCAC) for potential future inclusion of BPC-157 just got voted in

BPC 157 just got voted in favor to be added to the 503A Bulk Drug Substances list, meaning a huge step towards being able to be prescribed and compounded in the US. Thank FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! I just testified at an FDA meeting on whether seven popular peptides should be allowed in compounding. Just last month, FDA medical officers determined that none of the peptides met the agency's BPC 157 FDA Approval Status 2026: Clinical Trials

SKU: 66418985543 · From creatorsinfotech.com